Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma

16 Jul 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Endoplasmic Reticulum Stress and Disease
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31323387
DOI: 10.1016/j.jtho.2019.07.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung AdenocarcinomaPMID 31323387Read ↗

Integrative omics analysis identifies subtypes with therapeutic implications in lung adenocarcinoma harboring KEAP1/NFE2L2Semantic proximity Read ↗

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC).Semantic proximity Read ↗

Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.Semantic proximity Read ↗

The tumor suppressive role of KEAP1: Underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

Comprehensive genomic characterization of squamous cell lung cancers.Semantic proximity Read ↗

Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activationSemantic proximity Read ↗

In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancerSemantic proximity Read ↗

KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.Semantic proximity Read ↗

FOXA1 Targets NEK2 to Mediate Cisplatin Resistance in Lung Adenocarcinoma Cells by Activating DNA Damage RepairSemantic proximity Read ↗

An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.Semantic proximity Read ↗

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read ↗

Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.